GLTO_OUT_1 [2025-04-02 13:51:41 -0400] 2987 Bytes | 851 tokens | Cum: 851 tkns (10.64% of 8k)
==========================================================================

Listen up, partner—it's 1:51:40 PM on Wed Apr 02, 2025 -0400, and I’m revved up about Galecto (GLTO), climbing from 2.82 to 3.3. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Galecto (GLTO)
IPO: 2020-10-29 (4 Years Ago)
Market Cap: $3,729,052
Shares Outstanding: 1,320,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Here's the first list of news for Galecto:

C1 - Mar-19-25 04:45PM - Galecto Reports Full-Year 2024 Financial Results
C2 - Feb-06-25 08:00AM - Galecto to Participate in Upcoming Investor Conferences
C3 - Nov-14-24 09:55AM - Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
C4 - Nov-01-24 08:30AM - Galecto Reports Third Quarter 2024 Financial Results
C5 - Oct-18-24 08:15AM - Galecto price target raised to $10 from $9 at Oppenheimer
C6 - Oct-15-24 08:30AM - Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
C7 - Oct-07-24 08:45AM - Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
C8 - Aug-28-24 09:00AM - Galecto Announces Reverse Stock Split

Prior AI Reports for GLTO:
1. 2025-03-21 – Score: 45 – Target: 5.8000 – Highs: 7.3000 / 7.1000 / 6.62
galectos-mixed-signals-high-insider-ownership-amidst-financial-struggles

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Galecto (GLTO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GLTO_OUT_3 [2025-04-02 13:51:42 -0400] 1104 Bytes | 323 tokens | Cum: 1176 tkns (14.70% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Galecto Reports Full-Year 2024 Financial Results**
Date: Mar-19-25 04:45PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045829/0/en/Galecto-Reports-Full-Year-2024-Financial-Results.html

March 19, 2025 16:45 ET| Source:Galecto, Inc.Galecto, Inc.

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024.

“A significant moment for Galecto in 2024 was the completion of our strategic review, which solidified our commitment to advancing innovative oncology therapies,” said Dr. Hans Schambye, CEO of Galecto. “The acquisition of global rights to GB3226 provides us with an opportunity to develop a unique approach to AML that

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLTO_OUT_5 [2025-04-02 13:51:43 -0400] 935 Bytes | 297 tokens | Cum: 1475 tkns (18.44% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T13:18:00Z - Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON....
A2 - 2025-03-25T21:05:55Z - 12 Health Care Stocks Moving In Tuesday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), IMAC...
A3 - 2025-03-25T17:05:55Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - CNS Pharma (NASDAQ:CNSP), IMAC Hldgs (N...
A4 - 2025-03-21T17:05:38Z - 12 Health Care Stocks Moving In Friday's Intraday Session - GlucoTrack (NASDAQ:GCTK), CervoMed (NASD...
A5 - 2025-03-19T20:45:00Z - Galecto Reports Full-Year 2024 Financial Results...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GLTO_OUT_7 [2025-04-02 13:51:51 -0400] 1098 Bytes | 416 tokens | Cum: 1893 tkns (23.66% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON.**Date: 2025-03-26Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64934114-pre-market-movers-osrh-surg-blne-huma-tnon-020.htmOTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).

In the Green

OSR Holdings, Inc. (OSRH) is up over 173% at $4.37. SurgePays, Inc. (SURG) is up over 74% at $2.41. Beeline Holdings, Inc. (BLNE) is up over 52% at $2.86. GameStop Corp. (GME) is up over 15% at $29.38. Visionary Holdings Inc. (GV) is up over 11% at $3.56. Perimeter Solutions, Inc. (PRM) is up over 9% at $9.94. TherapeuticsMD, Inc. (TXMD) is up over 9% at $1.00. Titan America SA (TTAM) is up over 8% at $14.84. AleAnna, Inc. (ANNA) is up over 7% at $8.30. Global Interacti

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLTO_OUT_9 [2025-04-02 13:51:51 -0400] 938 Bytes | 306 tokens | Cum: 2400 tkns (30.00% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-06T13:00:00Z - Galecto to Participate in Upcoming Investor Conferences
B2 - 2024-10-07T12:45:00Z - Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
B3 - 2024-05-01T20:01:00Z - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
B4 - 2024-02-14T17:00:05Z - Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
B5 - 2024-02-14T10:48:00Z - New Strong Buy Stocks for February 14th
B6 - 2024-01-09T21:57:30Z - What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLTO_OUT_11 [2025-04-02 13:51:54 -0400] 633 Bytes | 188 tokens | Cum: 2590 tkns (32.38% of 8k)
==========================================================================

Showing B4 (chunk 1 of 1): B4:
**Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2226356/galecto-inc-glto-upgraded-to-strong-buy-what-does-it-mean-for-the-stockGalecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLTO_OUT_13 [2025-04-02 13:51:55 -0400] 1067 Bytes | 282 tokens | Cum: 2925 tkns (36.56% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following information should be read in conjunction with the audited CONS financial statements and notes thereto for the year ended December 31, 2024 included in this Annu...

S2 - 2025-03-19 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following information should be read in conjunction with the audited CONS financial statements and notes thereto for the year ended December 31, 2024 included in this Annu...

S7 - 2024-11-01 10-Q PART IFINANCI AL INFO

Item 1. Financi al Stmnts.

GALECTO, INC.

Condensed Consolidat ed Balance Sheets

(in thousands, except share and per share amounts)

September 30,

December 31,

Assets

(unaudited)

Curr assets

Cash and cash equiv

$

19...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLTO_OUT_15 [2025-04-02 13:51:55 -0400] 1098 Bytes | 233 tokens | Cum: 3160 tkns (39.50% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024 included in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth herein and in other SEC filings.

Overview

We are a clinical-stage biotechnology comp

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLTO_OUT_17 [2025-04-02 13:52:00 -0400] 1098 Bytes | 241 tokens | Cum: 3403 tkns (42.54% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): any developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and liver diseases. Our strategy is to focus on diseases without disease-modifying treatment options and where there is a high unmet medical need.

In September 2023, we announced a corporate restructuring that resulted in a substantial reduction of our workforce and that we had initiated a process to evaluate strategic alternatives. On October 7, 2024, we announced that we had completed our strategic alternative review process and determined to focus on oncology and severe liver diseases. In connection with this announcement, we announced that we had entered into the Bridge Purchase Agreement with Bridge Medicines, pursuant to which we acquired global rights to Bridge Medicines BRM-1420 program, a novel dual ENL-YEATS and FLT3 inhibitor for multiple gene

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLTO_OUT_19 [2025-04-02 13:52:12 -0400] 5937 Bytes | 1696 tokens | Cum: 5226 tkns (65.33% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 82,240 | Perf Month: -20.39% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 247.73K | Perf Quarter: -29.57% | Short Float: 2.43% | ROE: -91.62% |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.51 | Index: - | Short Ratio: 0.11 | ROI: -134.90% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 40.94 | Market Cap: 4.29M | Short Interest: 0.03M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.64 | Shs Outstand: 1.32M | Beta: 1.29 | EPS Surprise: -72.73% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: -21.65% | Shs Float: 1.14M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: -28.25% | Inst Own: 3.19% | Sales past 5Y: 0.00% | Earnings: Mar 19 AMC |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: -61.14% | Insider Own: 13.48% | Employees: 5 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: -17.77% | Insider Trans: -1.15% | Debt/Eq: 0.10 | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Galecto, Inc. (GLTO) by Schambye Hans T. (Chief Executive Officer) on 2025-01-03
- Common Stock: 2640 shares at $N/A (D)
- Common Stock: 1341 shares at $5.6 (D) Footnote: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- Restricted Stock Units: 2640 shares at $0 (D)
- Stock Option (right to buy): 16400 shares at $0 (D)

Inside Trans: Galecto, Inc. (GLTO) by Kronmiller Matthew (EVP Strategy and CBO) on 2025-01-03
- Stock Option (right to buy): 6000 shares at $0 (D)

Inside Trans: Galecto, Inc. (GLTO) by Firmani Lori (Interim CFO) on 2025-01-03
- Common Stock: 726 shares at $N/A (D)
- Common Stock: 261 shares at $5.63 (D) Footnote: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- Restricted Stock Units: 726 shares at $0 (D)
- Stock Option (right to buy): 5000 shares at $0 (D)

Inside Trans: Galecto, Inc. (GLTO) by Winslow Garrett (General Counsel) on 2025-01-03
- Common Stock: 1320 shares at $N/A (D)
- Common Stock: 471 shares at $5.6 (D) Footnote: Shares sold to cover tax obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its 2020 Equity Incentive Plan and does not represent a discretionary trade by the Reporting Person.
- Restricted Stock Units: 1320 shares at $0 (D)
- Stock Option (right to buy): 6000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 844000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -21439000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.26
Average Volume: 627069.39
30-Day High: 6.7
30-Day Low: 2.82

[Detailed Financials: TTM 2024]
- Total Assets: $17,132,000.0
- Total Liabilities: $1,301,000.0
- Total Equity: $15,831,000.0
- Current Assets: $16,839,000.0
- Current Liabilities: $1,197,000.0

[Income Statement: TTM 2024]
- Revenue: $844,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -18.53

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $317,000

[Detailed Financials: FY 2024]
- Total Assets: $17,132,000.0
- Total Liabilities: $1,301,000.0
- Total Equity: $15,831,000.0
- Current Assets: $16,839,000.0
- Current Liabilities: $1,197,000.0

[Income Statement: FY 2024]
- Revenue: $844,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -18.53

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $317,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GLTO_OUT_21 [2025-04-02 13:52:16 -0400] 676 Bytes | 167 tokens | Cum: 5644 tkns (70.55% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GLTO_IN_23 [2025-04-02 13:52:16 -0400] 126 Bytes | 29 tokens | Cum: 5758 tkns (71.97% of 8k)
==========================================================================

====================================
[2025-04-02 13:52:16] # Analysis Completed
Elapsed Time: 36.07 seconds